Summary

AI models are generating thousands of promising antibody variants faster than ever before. But because downstream mammalian expression and SPR validation are high-cost and time-consuming, teams are forced into a costly bottleneck—often over-investing in candidates that simply do not bind.

Join Sumit Kalsi, Associate Director of Product Research at Nuclera, for insights into the exclusive launch of Nuclera’s Rapid Antibody Screening Service. Discover how integrating a rapid, 96-plex cell-free binary expression and binding screen can act as the ultimate early filter for your pipeline.

Sumit will walk through the frictionless journey—from digital sequences to decision-grade data—and share validation data proving that cell-free produced IgG1 antibodies perfectly reproduce CHO binding profiles. Stop burning budget on non-binders and learn how to reserve your expensive mammalian scale-up exclusively for winning candidates.

In this webinar, you’ll learn how to:

• Shrink the list: cell-free binary screening confidently eliminates non-binders from your AI-generated libraries.
• Save your resources: Drastically reduce wasted downstream spend by advancing only confirmed hits into mammalian expression and full SPR.
• Accelerate your pipeline: Convert digital sequences into experimental wet-lab ground truth, rapidly, for roughly ~$100 per antibody.

By the end of the session, you’ll:

• Understand the mechanics of Nuclera’s automated binary expression and yes/no binding workflow.
• See the data proving that early cell-free screening is highly predictive of downstream CHO success.
• Know exactly how to integrate this rapid triage step into your existing discovery pipeline without adding CapEx or headcount.

This webinar is designed for:

• AI & Protein Design teams looking to validate models with wet-lab ground truth.
• Biopharma leaders wanting to de-risk pipelines before expensive scale-up.
• CRO platform teams seeking to reduce FTE and improve project turnaround.

Speaker: